Mechanistically, MEK1 signaling activation increased SIRT1 expression and protein stability and inhibited the proteasomal degradation of SIRT1; this promoted self-renewal and oncogenicity in LCSCs, resulting in poor prognosis of HCC patients (46). This evidence concerns the gene MAP2K1 and hepatocellular carcinoma.